Insider Selling: MiMedx Group, Inc. (NASDAQ:MDXG) Insider Sells 1,759 Shares of Stock

MiMedx Group, Inc. (NASDAQ:MDXG) insider Kimberly Maersk-Moller sold 1,759 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $8.04, for a total value of $14,142.36. Following the completion of the transaction, the insider now directly owns 309,077 shares in the company, valued at $2,484,979.08. This trade represents a 0.57 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Kimberly Maersk-Moller also recently made the following trade(s):

• On Thursday, March 13th, Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock. The stock was sold at an average price of $7.89, for a total value of $32,396.34.
• On Friday, February 28th, Kimberly Maersk-Moller sold 2,111 shares of MiMedx Group stock. The stock was sold at an average price of $8.40, for a total transaction of $17,732.40.

MiMedx Group Price Performance

MDXG opened at $7.94 on Friday. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The business’s fifty day simple moving average is $8.37 and its 200-day simple moving average is $7.86. The company has a market capitalization of $1.17 billion, a price-to-earnings ratio of 14.44 and a beta of 1.97. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The company had revenue of $92.91 million for the quarter, compared to analysts’ expectations of $89.42 million. On average, equities research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

Hedge Funds Weigh In On MiMedx Group

Several institutional investors have recently bought and sold shares of MDXG. Principal Financial Group Inc. boosted its position in MiMedx Group by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 55,495 shares of the company’s stock valued at $328,000 after acquiring an additional 3,292 shares in the last quarter. Victory Capital Management Inc. lifted its stake in shares of MiMedx Group by 2.8% during the 3rd quarter. Victory Capital Management Inc. now owns 142,350 shares of the company’s stock worth $841,000 after purchasing an additional 3,901 shares during the last quarter. Intech Investment Management LLC bought a new stake in MiMedx Group during the third quarter valued at about $119,000. Charles Schwab Investment Management Inc. grew its stake in MiMedx Group by 6.9% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock valued at $8,483,000 after purchasing an additional 92,726 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in MiMedx Group by 35.3% in the third quarter. The Manufacturers Life Insurance Company now owns 61,706 shares of the company’s stock worth $365,000 after purchasing an additional 16,083 shares in the last quarter. 79.15% of the stock is owned by hedge funds and other institutional investors.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.